Combination Strategies with Menin Inhibitors for Acute Leukemia.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-09-03 DOI:10.1158/2643-3230.BCD-24-0212

Ghayas C Issa, Sheng F Cai, Alex Bataller, Hagop M Kantarjian, Eytan M Stein

引用次数: 0

Abstract

Menin inhibitors are targeted therapies for the treatment of genetically defined subsets of acute leukemia. The menin inhibitor revumenib is currently approved for relapsed or refractory leukemia with rearrangement of lysine methyltransferase 2 A (KMT2A). However, multiple other menin inhibitors are currently in clinical development aimed at targeting additional subsets such as nucleophosmin 1 (NPM1) mutations which form up to 30% of acute myeloid leukemia. As observed with other targeted therapies for cancer, on-target resistance mutations emerged in advanced cases following monotherapy. Therefore, combination strategies incorporating menin inhibitors are needed to improve durability and depth of remission.

查看原文本刊更多论文

Menin抑制剂联合治疗急性白血病。

Menin抑制剂是治疗急性白血病基因亚群的靶向疗法。menin抑制剂revumenib目前被批准用于复发或难治性白血病赖氨酸甲基转移酶2a （KMT2A）重排。然而，多种其他menin抑制剂目前正处于临床开发阶段，旨在靶向其他亚群，如核磷蛋白1 （NPM1）突变，该突变构成高达30%的急性髓系白血病。正如在其他癌症靶向治疗中观察到的那样，单药治疗后的晚期病例出现了靶向耐药突变。因此，需要结合menin抑制剂的联合策略来提高缓解的持久性和深度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.